Fritz P M, DeHaven-Hudkins D L, Fleissner L C, Ford-Rice F Y, Luttinger D
Department of Neuroscience, Sterling-Winthrop Pharmaceutical Research Division, Rensselaer, NY 12144.
Eur J Pharmacol. 1993 Apr 28;235(2-3):229-35. doi: 10.1016/0014-2999(93)90141-4.
Several relatively selective compounds with affinity for the sigma binding site were assessed for their ability to inhibit apomorphine-induced climbing in the mouse. Although, the majority of compounds inhibited apomorphine-induced climbing, there was no correlation between the ability to inhibit climbing and potency in sigma binding assays using [3H]1,3-di-o-tolylguanidine (DTG) or 3H-pentazocine as ligands. The potency of the compounds to inhibit binding to muscarinic M1 or M2 receptors correlated with the potency to inhibit apomorphine-induced climbing. However, several of the compounds that inhibit climbing had microM affinity at muscarinic receptors. Whether these concentrations were achieved in vivo is unclear. Our data suggest that sigma activity per se is not responsible for inhibition of apomorphine-induced climbing.
评估了几种对σ结合位点具有亲和力的相对选择性化合物抑制小鼠阿扑吗啡诱导攀爬的能力。尽管大多数化合物抑制了阿扑吗啡诱导的攀爬,但在使用[3H]1,3-二邻甲苯基胍(DTG)或3H-喷他佐辛作为配体的σ结合试验中,抑制攀爬的能力与效力之间没有相关性。这些化合物抑制与毒蕈碱M1或M2受体结合的效力与抑制阿扑吗啡诱导攀爬的效力相关。然而,几种抑制攀爬的化合物对毒蕈碱受体具有微摩尔亲和力。尚不清楚这些浓度在体内是否能够达到。我们的数据表明,σ活性本身并不负责抑制阿扑吗啡诱导的攀爬。